MINSHENG ROYAL FUND MANAGEMENT CO BIOTECHNOLOGY ETF CNYMINSHENG ROYAL FUND MANAGEMENT CO BIOTECHNOLOGY ETF CNYMINSHENG ROYAL FUND MANAGEMENT CO BIOTECHNOLOGY ETF CNY

MINSHENG ROYAL FUND MANAGEMENT CO BIOTECHNOLOGY ETF CNY

No trades
See on Supercharts

Key stats


Assets under management (AUM)
Fund flows (1Y)
Dividend yield (indicated)
Discount/Premium to NAV
Shares outstanding
Expense ratio
0.60%

About MINSHENG ROYAL FUND MANAGEMENT CO BIOTECHNOLOGY ETF CNY


Issuer
Minsheng Royal Fund Management Co., Ltd.
Brand
Minsheng Royal
Inception date
Aug 5, 2021
Structure
Open-Ended Fund
Index tracked
CSI Biotechnology Theme Index - CNY - Benchmark TR Gross
Replication method
Physical
Management style
Passive
Dividend treatment
Distributes
Primary advisor
Minsheng Royal Fund Management Co., Ltd.
ISIN
CNE100004X99
Closely track the target index, pursue the minimization of tracking deviation and tracking err, and strive to achieve Long-term investment income consistent with the performance of the underlying index.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Biotechnology
Strategy
Vanilla
Geography
China
Weighting scheme
Market cap
Selection criteria
Market cap

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of December 31, 2024
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks96.42%
Health Technology92.35%
Transportation1.12%
Commercial Services1.05%
Producer Manufacturing0.71%
Health Services0.66%
Distribution Services0.52%
Bonds, Cash & Other3.58%
Cash3.58%
Stock breakdown by region
2%97%
Asia97.81%
Europe2.19%
North America0.00%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows



Frequently Asked Questions


516930 invests in stocks. The fund's major sectors are Health Technology, with 92.35% stocks, and Transportation, with 1.12% of the basket. The assets are mostly located in the Asia region.
516930 top holdings are Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A and WuXi AppTec Co., Ltd. Class A, occupying 10.19% and 9.68% of the portfolio correspondingly.
No, 516930 doesn't pay dividends to its holders.
516930 shares are issued by Minsheng Royal Fund Management Co., Ltd. under the brand Minsheng Royal. The ETF was launched on Aug 5, 2021, and its management style is Passive.
516930 expense ratio is 0.60% meaning you'd have to pay 0.60% of your investment to help manage the fund.
516930 follows the CSI Biotechnology Theme Index - CNY - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
516930 invests in stocks.